Investigational Drug Information for Quisinostat
✉ Email this page to a colleague
What is the drug development status for Quisinostat?
Quisinostat is an investigational drug.
There have been 3 clinical trials for Quisinostat.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2015.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Carcinoma, Ovarian Epithelial, and Lymphoma. The leading clinical trial sponsors are Janssen Pharmaceutica N.V., Belgium, NewVac LLC, and Janssen Research & Development, LLC.
Summary for Quisinostat
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 412 |
WIPO Patent Applications | 375 |
Japanese Patent Applications | 96 |
Clinical Trial Progress | Phase 2 (2015-09-01) |
Vendors | 0 |
Recent Clinical Trials for Quisinostat
Title | Sponsor | Phase |
---|---|---|
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | Janssen Pharmaceutica N.V., Belgium | Phase 2 |
Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | NewVac LLC | Phase 2 |
Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | Janssen Pharmaceutica N.V., Belgium | Phase 1 |
Clinical Trial Summary for Quisinostat
Top disease conditions for Quisinostat
Top clinical trial sponsors for Quisinostat
US Patents for Quisinostat
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |